BBT001

DRUG3 trials

Sponsors

Bambusa Therapeutics

Conditions

Atopic DermatitisChronic Spontaneous Urticaria

Phase 1

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

RecruitingNCT06808477

Bambusa TherapeuticsAtopic Dermatitis

Start: 2025-02-27End: 2027-02-28Target: 237Updated: 2026-08-13

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

RecruitingNCT07239947

Bambusa TherapeuticsAtopic Dermatitis

Start: 2025-08-09End: 2028-06-30Target: 99Updated: 2026-07-22

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)

RecruitingNCT07717905

Bambusa TherapeuticsChronic Spontaneous Urticaria

Start: 2026-06-29End: 2028-06-30Target: 48Updated: 2026-07-22